Another take-out message is that direct testing for mTOR activation, which in our case was carried out by combined 4E-BP1 IHC or WB, should be performed for personalized enrollment of patients in mTOR inhibitor trials, as it may reveal tumor populations or subpopulations that do not harbor mTOR activation. Here, MTOR is linked to neoplasm.